August 2016, Vol. 5, No. 6
Presenting Emerging Data and Calling for Molecular Tumor Board Case StudiesLetter to Our Readers
On behalf of all of us at Personalized Medicine in Oncology (PMO), I hope you are enjoying the summer and finding time for the recreation necessary to return to the care of your patients with a renewed spirit. After the busy ASCO season, we have taken advantage of this time to review data from this important meeting and are pleased to offer the most critical information in this issue. You’ll find a host of the best reports from ASCO all related to personalized medicine, from the latest in immunotherapies and matching therapy to molecular alterations. We hope this compilation is of value to you and your practice.
Also in this issue, we are delighted to feature an article by PMO Editorial Board member Darren Sigal, MD, and his colleague David Hermel, MD. The authors take a critical look at emerging data regarding anti–PD-1 agents as biomarkers.
Many oncology centers host molecular tumor boards during which multidisciplinary participants discuss patients with all types of cancer whose tumors have been analyzed with advanced genomic diagnostic tests. If you participate in such a board, we want to hear from you with your case study submissions for our Molecular Tumor Board department. Submissions should include case presentation, actionable biomarker identification, therapeutic course, and outcomes. Author guidelines can be found at www.personalizedmedonc.com/author-guidelines.
Enjoy what remains of summer, and we hope you will consider submitting a case study. Thank you for your loyal readership.
Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology
Access and adherence to long-term cancer therapies are emerging as major public health issues around the world, as high out-of-pocket costs for oral anticancer agents are linked with noncompliance that can directly affect outcomes.“Solutions should involve increasing access and reducing cost – especially out-of-pocket costs,” said Dawn L. Hershman, MD, [ Read More ]
Serial vaccination with galinpepimut-S (GPS) induces immunologic responses in patients with acute myeloid leukemia (AML) who are in remission. Both disease-free survival (DFS) and overall survival (OS) appear to be improved in AML patients with an immune response to GPS, according to data from a phase 2 trial of GPS. [ Read More ]